IMA30X Series (ACTengine®)
Various solid tumors
Pre-clinicalResearch
Key Facts
About Immatics
Immatics is dedicated to developing transformative T-cell receptor (TCR) therapies to address the significant unmet need in solid tumors. Its core strength lies in its proprietary discovery platforms that identify novel, cancer-specific targets presented by HLA molecules, enabling the development of highly specific TCR-based therapeutics. The company has established strategic partnerships with major players like Bristol Myers Squibb and has multiple clinical-stage assets, including TCR-T cell therapies and TCR Bispecifics, positioning it at the forefront of the next wave of immuno-oncology.
View full company profileTherapeutic Areas
Other Various solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Individualized mRNA Cancer Immunotherapies | BioNTech | Phase 2/3 |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved |
| RP2 / RP2 + nivolumab | Replimune | Phase 1 |
| Bicycle Toxin Conjugates (BTCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Bicycle Radio Conjugates (BRCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Micvotabart pelidotin (MICVO) | Pyxis Oncology | Phase 1 |
| OST-tADC Platform | OS Therapies | Pre-clinical |